Tenofovir disoproxil fumarate (TDF) is a nucleotide reverse transcriptase inhibitor that has been widely used for the treatment of patients with human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections. Despite the excellent safety records of this regimen, a few cases of acute renal failure and Fanconi syndrome have been reported among HIV patients exposed to TDF. However, in the HBV monoinfection scenario, only five cases of TDF-associated Fanconi syndrome have been reported thus far, two of them providing a confirmatory kidney biopsy. Here, we describe the case of a 68-year-old woman with chronic hepatitis B (CHB) who developed TDF-induced Fanconi syndrome that reverted after TDF withdrawal from tenofovir alafenamide. Though the overall risk of TDF-associated severe renal toxicity in HBV patients appears to be negligible, both glomerular and tubular functions should be monitored in patients exposed to TDF.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672342PMC
http://dx.doi.org/10.3390/jcm12227178DOI Listing

Publication Analysis

Top Keywords

fanconi syndrome
16
syndrome reported
8
patients exposed
8
exposed tdf
8
tenofovir-induced fanconi
4
syndrome
4
syndrome presenting
4
presenting life-threatening
4
life-threatening hypokalemia
4
hypokalemia review
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!